Skip to Content

Alcon Inc

ALC: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$12.00WrmzmsNstmsksf

Alcon: Solid Q2 Results Despite Foreign Exchange Headwinds, Adjusted Growth and Margin Meet Targets

Narrow-moat Alcon continued its strong start to the year as the company benefited from portfolio growth in contact lenses (Total1 for astigmatism, Total30) and cataract procedure recovery in international markets. Though top-line numbers were affected by currency headwinds, leading management to slightly lower guidance for the remainder of the year, we are maintaining our fair value estimate at $53, and shares look moderately overvalued in our view.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ALC so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center